MarginsXMarginsX
Home › Markets › Health Care › TCRT

Alaunos Therapeutics Inc. (TCRT)

TCRT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.60
-1.84% on the day
Market cap
$6.7M
Nano cap
Revenue · 2025
$5K
-50.0% on 2024
Net income · 2025
-$4.2M
-83520.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/0001193125-26-134720-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTCRT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001107421
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$5K
Net income-$4.2M
Operating income-$4.2M
Net margin-83520.0%
Operating margin-84500.0%
Revenue growth-50.0%
Cash$1.4M
Total assets$3.0M
P/E (computed)Net income was not positive
P/S (computed)1346.7×

Warning signs

Cash runway
0.5 months
$124K cash at June 30, 2026
Share count, 1 year
+15.7%
2025-08-14 to 2026-08-14 · +58.4% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which r"
10-Q 2026-08-14
Cash and burn$124K cash; operating cash flow -$682K a quarter.Report 2026-06-30
Shares outstanding2,540,480 (2026-08-14); 2,194,941 a year earlier; 240,627,055 three years earlier. 3y figure adjusted for splits (1-for-150 overall).Cover page 2026-08-14
Reverse splits, 3 years2; latest 1-for-10 on 2024-07-18Source 2024-07-18
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-13
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-10-09
AuditorCherry Bekaert LLP, Tampa, Florida, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 4,128,460 shares at the 2026-11-13 price; the latest SEC cover count is 2,540,480 as of 2026-08-14. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$0-$952K-$300K$124KNo debt tags$3K10-Q 2026-08-14
Q1 2026
2026-03-31
$0-$1.0M-$1.0M$354KNo debt tags$3K10-Q 2026-05-15
Q4 2025
2025-12-31
$3K-$893K-$552K$1.4MNo debt tags$5K10-K 2026-03-31
Q3 2025
2025-09-30
$0-$1.2M-$844K$1.9MNo debt tags$6K10-Q 2025-11-14
Q2 2025
2025-06-30
$0-$1.1M-$701K$2.9MNo debt tags$6K10-Q 2026-08-14
Q1 2025
2025-03-31
$2K-$1.1M-$772K$319KNo debt tags$10K10-Q 2026-05-15
Q4 2024
2024-12-31
$4K-$742K-$592K$1.1M$0$9K10-K 2026-03-31
Q3 2024
2024-09-30
$0-$1.1M-$781K$1.7MNo debt tags$6K10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-13
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-10-23
Latest proxyPRE 14A2026-11-13

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.3%
1 month-46.2%
3 months-18.1%
Year to date-49.5%
1 year-42.8%
From 52-week high-62.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SNGXSoligenix Inc.$0.2882-10.22%$6.7M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
ADXNAddex Therapeutics Ltd$3.83-5.67%$6.5M
XCURExicure Inc.$1.07-0.93%$7.0M
ENVBEnveric Biosciences Inc.$1.44-4.95%$6.4M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
IMRNImmuron Limited$0.8996+2.23%$7.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier